Literature DB >> 21173509

Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application.

Anna Guerra1, Maria Rosaria Sapio, Vincenzo Marotta, Elisabetta Campanile, Maria Ilaria Moretti, Maurilio Deandrea, Manuela Motta, Paolo Piero Limone, Gianfranco Fenzi, Guido Rossi, Mario Vitale.   

Abstract

Fine-needle aspiration cytology (FNAC) is the primary means to distinguish benign thyroid nodules from malignant ones. About 20% of FNAC yields indeterminate results leading to unnecessary or delayed surgery. Many studies of tissue samples, the majority of which are retrospective advocate testing for RET rearrangements as a diagnostic adjunctive tool in thyroid nodules with indeterminate cytological findings. Because of the uncertain prevalence of RET rearrangements, its utility as a tumor marker is still controversial. The goal of this study was to establish the prevalence and the utility of testing for RET rearrangements in FNAC suspicious of cancer in a clinical setting. In this prospective study, we analysed a large series of thyroid aspirates by RT-PCR only and Southern blot on RT-PCR products for type 1 and 3 RET rearrangements. Results were compared with clinical findings, cytological diagnosis and final histopathology. By the higher sensitive Southern-blot on RT-PCR method, RET rearrangements were present in 36% of papillary thyroid carcinomas (RET/PTC-1, 12%; RET/PTC-3, 20%; both, 4%) and of 13.3% of benign nodules. By means of RT-PCR only, RET rearrangements were disclosed only in 14.3% of PTC and in 3.6% of benign nodules. No significant correlation was found between RET rearrangements and clinicopathological features of patients. These results indicate that molecular testing of thyroid nodules for RET/PTC must take into account of its high prevalence in benign nodules, inducing false positive diagnoses when the highly sensitive assay Southern-blot on RT-PCR is used. Its searching by means of RT-PCR only, has a specificity superior of conventional cytology and can be used to refine inconclusive FNAC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21173509     DOI: 10.1507/endocrj.k10e-260

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  26 in total

Review 1.  Coding Molecular Determinants of Thyroid Cancer Development and Progression.

Authors:  Veronica Valvo; Carmelo Nucera
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

Review 2.  Values of molecular markers in the differential diagnosis of thyroid abnormalities.

Authors:  T M P B Tennakoon; M Rushdhi; A D C U Ranasinghe; R S Dassanayake
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-22       Impact factor: 4.553

3.  RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.

Authors:  Mosin S Khan; Qurteeba Qadri; Mudasir J Makhdoomi; Muneer A Wani; Aejaz A Malik; Madiha Niyaz; Shariq R Masoodi; Khurshid I Andrabi; Rauf Ahmad; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2018-11-22       Impact factor: 3.201

Review 4.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

Review 5.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

6.  CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells.

Authors:  Lei Cui; Qing Zhang; Zhengfa Mao; Jixiang Chen; Xuqing Wang; Jianguo Qu; Jianxin Zhang; Dayong Jin
Journal:  Tumour Biol       Date:  2011-04-20

7.  BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature Review.

Authors:  Ahmet Şahpaz; Binnur Önal; Ahmet Yeşilyurt; Ünsal Han; Tuncay Delibaşı
Journal:  Balkan Med J       Date:  2015-04-01       Impact factor: 2.021

8.  BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma.

Authors:  Anna Guerra; Vincenzo Marotta; Maurilio Deandrea; Manuela Motta; Paolo Piero Limone; Alessia Caleo; Pio Zeppa; Silvano Esposito; Franco Fulciniti; Mario Vitale
Journal:  Endocrine       Date:  2012-12-01       Impact factor: 3.633

9.  BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay.

Authors:  Anna Guerra; Vincenza Di Stasi; Pio Zeppa; Antongiulio Faggiano; Vincenzo Marotta; Mario Vitale
Journal:  Endocrine       Date:  2013-06-18       Impact factor: 3.633

Review 10.  Progress in molecular-based management of differentiated thyroid cancer.

Authors:  Mingzhao Xing; Bryan R Haugen; Martin Schlumberger
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.